CRISPR-Cas9 gene editing is one of the most important breakthroughs of the 21st century

The CRISPR Collective is dedicated to informing the public and news media about the scientific and legal history of this technology

Learn more Arrow-right

"CRISPR Therapeutics, Intellia Therapeutics and Caribou Biosciences Provide Update on U.S Federal Circuit Decision Upholding the Ruling by U.S. Patent and Trademark Office in Interference Proceeding Relating to CRISPR/Cas9 Genome Editing Technology” September 10, 2018

Read more Arrow-right

Introduction to CRISPR-Cas9 Gene Editing

CRISPR-Cas9 is the first technology of its kind to allow versatile, efficient and reliable genome editing.

Learn more Arrow-right


We answer some of the most commonly asked questions on the CRISPR-Cas9 intellectual property situation globally.

Learn more Arrow-right

The First Year of CRISPR-Cas9 Gene Editing

Explore Arrow-right